Abstract 66P
Background
Treatment options are limited for patients with advanced or metastatic solid tumors after failure of standard therapies. Utidelone, a genetically engineered epothilone analogue, has demonstrated high activity in clinical studies against a broad range of tumors using regimen of 30mg/m2, iv, d1-5 every 21 day. This study aimed to evaluate the efficacy and safety for solid tumors using 120h continuous intravenous infusion of utidelone.
Methods
This is a prospective, multicenter, single-arm trial. We included patients aged 18 years or older with metastatic solid tumor after failure of standard therapies. Utidelone was administrated at 150 mg/m2 via 120h continuous intravenous infusion, alone or in combination with other anticancer agents every 21 days until disease progression or intolerable toxicity. The primary endpoints were ORR and safety. Secondary endpoints included mPFS, DCR and QoL.
Results
As data cut-off on June 30, 2023, a total of 50 patients were enrolled and analyzed. There were 20 patients with breast cancers,11 with gynecological cancers, 8 with gastrointestinal cancers, 6 with lung cancer and 5 with other solid tumors. The median number of previous systemic therapies was three. 38 (76%) patients had taxane-refractory diseases. The overall ORR and DCR was 20% and 66%, respectively, the mPFS was 4 months. For breast cancer patients, the ORR and DCR was 40% and 75%, respectively, and the mPFS was 6 months. For gynecological cancers, the ORR and DCR was 9% and 64%, respectively. Most of the AEs were grade 1 or 2 and were manageable and reversible. The rate of grade ≥3 AEs including peripheral neuropathy was 4% (2/50). No treatment-related discontinuation or deaths occurred.
Conclusions
This study demonstrated a promising anti-tumor activity of utidelone in patients with metastatic solid tumors after failure of the standard therapies, especially in patients with breast cand gynecological cancers. Moreover, 120h continuous intravenous infusion is a more tolerable administration method than 5 days intermittent infusion, worthy further study.
Clinical trial identification
ChiCTR2300074299.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract